INFORMATION FOR
News
In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.
On Tuesday, September 19, 2023, experts from Smilow Cancer Hospital and Yale Cancer Center shared: Perspectives on the USPSTF Breast Screening Recommendations.
Lajos Pusztai, MD, DPhil, discusses key takeaways from analysis of the KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy in the neoadjuvant or adjuvant setting for patients with triple-negative breast cancer.
Treatment outcomes were similar between Black and non-Black patients with triple-negative breast cancer who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy, according to phase I/II clinical trial results published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Lajos Pusztai, MD, DPhil, discusses multiple analyses of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy administered in the neoadjuvant or adjuvant setting to patients with triple-negative breast cancer versus placebo plus chemotherapy.
Lajos Pusztai, MD, DPhil speaks about the Cancer Relevance of Human Genes.
Caryn Sullivan, 48, is a wife and mother, and she is also a fighter. At 31 as a newlywed, she had her first breast cancer diagnosis after a lump was discovered.
Dr. Sanft explains her role as a breast medical oncologist, as well as Director of the Survivorship Clinic and Patient Experience Officer.
In HER2-positive early stage (stage I-II) breast cancer, several different preoperative (also called neoadjuvant) chemotherapy options exist, each of these is associated with a different rate of complete eradication of cancer from the breast and lymph nodes (called pathologic complete response or pCR). Patients who experience pCR have excellent long term survival.
A new study led by Yale Cancer Center (YCC) researchers shows women with high-risk HER2-negative breast cancer treated before surgery with immunotherapy, plus a PARP inhibitor with chemotherapy, have a higher rate of complete eradication of cancer from the breast and lymph nodes compared to chemotherapy alone.
Using an investigative telephone text messaging protocol, clinicians were able to help women diagnosed with breast cancer remain on their endocrine therapy and get them through often difficult musculoskeletal adverse events, researchers reported here.
In an interview, Rachel Perry, PhD, discusses the link between insulin and cancer, a surprising finding in her research, and the future of precision medicine for metabolism-related cancers.
Smilow Shares with Primary Care: Breast Cancer
Eric Winer, MD, the director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital in New Haven, Connecticut, tells SELF that there’s not quite a consensus on when cis women and people assigned female at birth should begin getting mammograms.
Monica G. Valero, MD, assistant professor of surgery (oncology) and director of the Hispanic Breast Cancer Program, has received a prestigious one-year pilot grant from the American Cancer Society (ACS) to advance breast cancer care among the Hispanic population. The prestigious award affirms the Department of Surgery’s commitment to tackling health inequities on a national scale and locally.
No matter how metastatic breast cancer affects your love life, intimacy with your partner can still be meaningful and enjoyable.
Smilow Cancer Hospital, in partnership with the Norma Pfriem Breast Center, has opened a new patient care location in Bridgeport, CT to provide residents in the greater Bridgeport area with convenient access to Smilow Cancer Hospital specialty breast surgical care and expertise.
The Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center provides coordinated, state-of-the-art care for patients with benign and malignant diseases of the breast.
The Prudence Stiltor Crozier Breast Surgical Oncology Annual Lectureship and Resource Fund, to be guided by Mehra Goldhan, MD, MBA, aims to educate the next generation of breast surgeons.
Ellie Proussaloglou, MD, assistant professor of surgery (breast surgical oncology) discusses her fellowship at Yale and the transition from fellowship to being an attending.